1. Date of report to or resolution by the Board of Directors: 115/05/12 2. Date of approval by the Audit Committee: 115/05/12 3. Reporting period for financial report or annual self-reported financial information (XXX/XX/XX~XXX/XX/XX): 115/01/01~115/03/31 4. Cumulative operating revenue from January 1 to this period (thousand yuan): 1,651,875 5. Cumulative gross profit (loss) from January 1 to this period (thousand yuan): 720,594 6. Cumulative operating profit (loss) from January 1 to this period (thousand yuan): 343,566 7. Cumulative profit (loss) before tax from January 1 to this period (thousand yuan): 375,262 8. Cumulative net profit (loss) for the period from January 1 to this period (thousand yuan): 298,593 9. Cumulative net profit (loss) attributable to the parent company owner from January 1 to this period (thousand yuan): 231,520 10. Cumulative basic earnings (loss) per share from January 1 to this period (yuan): 1.30 11. Total assets at the end of the period (thousand yuan): 12,101,182 12. Total liabilities at the end of the period (thousand yuan): 3,029,345 13. Equity attributable to the parent company owner at the end of the period (thousand yuan): 6,041,189 14. Other matters to be notified: NA Keywords: Material Information

FACT BOX

  • Source: PR Times
  • Category: News
  • Dates in source: 115/05/12 / 115/01/01~115/03/31
  • Products / services: Pharmaceutical Products